Worth reading
65In focus
Scored from 4 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
19
%Wording
Definitive
How definitive the wording is.Revised forecast
Fiscal year ended June 2025 · Full yearNet Sales—→—Millions of yen
—
Ordinary income—→—Millions of yen
—
Profit attributable to owners of the parent—→—Millions of yen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
ELITechGroupおよびその他主要取引先の受注増加、海外連結子会社・合弁会社の解散を含む事業再編による費用抑制、核酸抽出試薬・消耗品の受注増加、大館試薬センターの稼働率向上による売上総利益率の改善。
Previous-period results売上高3,775百万円、経常利益-798百万円、当期純利益-917百万円、1株当たり当期純利益-33円21銭
Consolidated / non-consolidatedNon-consolidated
| Item | Details |
|---|---|
| Net Sales | 735 |
| Ordinary income | 714 |
| Profit attributable to owners of the parent | 730 |
| Fiscal Period Covered | Fiscal year ended June 2025 |
| Period Covered | Full year |
| Previous-period results | 売上高3,775百万円、経常利益-798百万円、当期純利益-917百万円、1株当たり当期純利益-33円21銭 |
| Reason for the revision | ELITechGroupおよびその他主要取引先の受注増加、海外連結子会社・合弁会社の解散を含む事業再編による費用抑制、核酸抽出試薬・消耗品の受注増加、大館試薬センターの稼働率向上による売上総利益率の改善。 |
| Consolidated / non-consolidated | Non-consolidated |
Items this document does not state (5)
Operating profitNet income per sharePublication date of previous forecastDetails and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、主要顧客ELITechGroup向けの臨床診断装置・試薬・消耗品・スペアパーツの受注増加と、その他主要取引先の受注増加によるもの。損失の改善は、海外連結子会社および合弁会社の解散を含む事業再編による費用抑制、核酸抽出試薬・消耗品の受注増加、大館試薬センターの稼働率向上による売上総利益率の改善によるもの。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.